Literature DB >> 28286191

Increased Intestinal Permeability in Relatives of Patients With Crohn's Disease Is Not Associated With Small Bowel Ulcerations.

Christopher W Teshima1, Karen J Goodman2, Mohamed El-Kalla2, Samina Turk2, Wael El-Matary3, Rosica Valcheva2, Ronda Danchak4, Marilyn Gordon4, Peter Ho2, Amanda Mullins4, Daniel Wong2, Dina Kao2, Jonathan Meddings5, Hien Huynh4, Levinus A Dieleman6.   

Abstract

BACKGROUND & AIMS: Many first-degree relatives of patients with Crohn's disease (CD) have increased intestinal permeability. Video capsule endoscopy (VCE) is the most sensitive imaging test to identify small bowel mucosal lesions that could indicate subclinical CD. We aimed to estimate the association of increased intestinal permeability with small bowel ulcerations detectable by VCE in healthy first-degree relatives of patients with CD.
METHODS: We conducted a cross-sectional study of 223 healthy, asymptomatic first-degree relatives of patients with CD (parents, siblings, and children; 9-45 years old) enrolled at the University of Alberta between 2009 and 2012. Patients were given the lactulose and mannitol test to measure small bowel permeability; we used high-performance liquid chromatography to measure concentrations of lactulose and mannitol in urine samples (increased permeability defined as a ratio of lactulose/mannitol 0.025 or greater). Patients with increased permeability (n = 39) and randomly selected subjects with normal permeability (n = 59) were then examined by VCE for signs of small bowel inflammation and subclinical CD. The prevalence of small bowel lesions was compared among groups. We performed logistic regression analyses to estimate odds ratios for the association of small bowel ulcerations with intestinal permeability.
RESULTS: Among 223 first-degree relatives of patients with CD, 30% were found to have increased intestinal permeability; VCE examination found 24% of subjects to have 3 or more small bowel ulcers. Three or more small bowel ulcers were detected in 28% of patients with increased intestinal permeability and 20% of patients with normal intestinal permeability (P = .37). The adjusted odds ratio for the association of 3 or more small bowel ulcers with increased intestinal permeability was 1.5 (95% confidence interval, 0.6-3.8; P = .46).
CONCLUSIONS: Thirty percent of healthy, asymptomatic first-degree relatives of patients with CD have increased intestinal permeability. However, a strong association of small bowel ulceration seen on VCE with increased intestinal permeability was not observed.
Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Family Member; Inflammatory Bowel Disease; Pathogenesis; Risk Factor

Mesh:

Year:  2017        PMID: 28286191     DOI: 10.1016/j.cgh.2017.02.028

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  11 in total

1.  Increased Gut Permeability in First-degree Relatives of Children with Irritable Bowel Syndrome or Functional Abdominal Pain.

Authors:  Mark McOmber; Danny Rafati; Kevin Cain; Sridevi Devaraj; Erica M Weidler; Margaret Heitkemper; Robert J Shulman
Journal:  Clin Gastroenterol Hepatol       Date:  2019-05-14       Impact factor: 11.382

Review 2.  Exploring the Early Phase of Crohn's Disease.

Authors:  Giorgos Bamias; Fabio Cominelli
Journal:  Clin Gastroenterol Hepatol       Date:  2020-09-16       Impact factor: 13.576

3.  Inter-kingdom effect on epithelial cells of the N-Acyl homoserine lactone 3-oxo-C12:2, a major quorum-sensing molecule from gut microbiota.

Authors:  Cécilia Landman; Jean-Pierre Grill; Jean-Maurice Mallet; Philippe Marteau; Lydie Humbert; Eric Le Balc'h; Marie-Anne Maubert; Kevin Perez; Wahiba Chaara; Loic Brot; Laurent Beaugerie; Harry Sokol; Sophie Thenet; Dominique Rainteau; Philippe Seksik; Elodie Quévrain
Journal:  PLoS One       Date:  2018-08-29       Impact factor: 3.240

4.  Transdermal fluorescence detection of a dual fluorophore system for noninvasive point-of-care gastrointestinal permeability measurement.

Authors:  Richard B Dorshow; J R Johnson; Martin P Debreczeny; I Rochelle Riley; Jeng-Jong Shieh; Thomas E Rogers; Carla Hall-Moore; Nurmohammad Shaikh; L Colleen Rouggly-Nickless; Phillip I Tarr
Journal:  Biomed Opt Express       Date:  2019-09-13       Impact factor: 3.732

Review 5.  Capturing the Biologic Onset of Inflammatory Bowel Diseases: Impact on Translational and Clinical Science.

Authors:  Dario Sorrentino; Vu Q Nguyen; Maithili V Chitnavis
Journal:  Cells       Date:  2019-06-06       Impact factor: 6.600

6.  Serum Zonulin Measured by Commercial Kit Fails to Correlate With Physiologic Measures of Altered Gut Permeability in First Degree Relatives of Crohn's Disease Patients.

Authors:  Namita Power; Williams Turpin; Osvaldo Espin-Garcia; Michelle I Smith; Kenneth Croitoru
Journal:  Front Physiol       Date:  2021-03-25       Impact factor: 4.566

7.  Functional Food Components, Intestinal Permeability and Inflammatory Markers in Patients with Inflammatory Bowel Disease.

Authors:  Joana Franco Lacerda; Ana Catarina Lagos; Elisabete Carolino; Ana Santos Silva-Herdade; Manuel Silva; Catarina Sousa Guerreiro
Journal:  Nutrients       Date:  2021-02-16       Impact factor: 5.717

Review 8.  Diagnosis and natural history of preclinical and early inflammatory bowel disease.

Authors:  Iago Rodríguez-Lago; Yamile Zabana; Manuel Barreiro-de Acosta
Journal:  Ann Gastroenterol       Date:  2020-06-22

9.  Are hospitalized patients with inflammatory bowel disease at increased risk of invasive bacterial infections? Results from POLIBD 3-year cohort study.

Authors:  Jolanta Gruszecka; Rafał Filip
Journal:  Gut Pathog       Date:  2021-02-22       Impact factor: 4.181

Review 10.  Micronutrient Improvement of Epithelial Barrier Function in Various Disease States: A Case for Adjuvant Therapy.

Authors:  Katherine M DiGuilio; Elizabeth Rybakovsky; Reza Abdavies; Romy Chamoun; Colleen A Flounders; Ariel Shepley-McTaggart; Ronald N Harty; James M Mullin
Journal:  Int J Mol Sci       Date:  2022-03-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.